出售蒂佳婷？雅诗兰黛再瘦身

Core Viewpoint - Estée Lauder is considering selling its Korean beauty brand, Dr. Jart+, amid declining performance and increasing market competition, reflecting a strategic shift towards more promising brands [1][4]. Group 1: Brand Performance and Market Context - Dr. Jart+ was established in 2004 and gained popularity with its "post-medical" positioning, expanding internationally with significant sales growth, particularly in the U.S. and China [3][4]. - After Estée Lauder acquired a one-third stake in Dr. Jart+'s parent company, Have & Be, in 2015, the brand's sales surged from 863 billion KRW to 4.898 trillion KRW by 2018, marking over a fivefold increase [4]. - However, Dr. Jart+'s growth has not sustained, with projected revenues for 2025 at approximately $150 million, significantly below the initial target of $500 million [4]. Group 2: Financial Performance of Estée Lauder - Estée Lauder's financial reports indicate a troubling trend, with net sales for fiscal year 2025 dropping to $14.326 billion, an 8% decline, and a net loss of $1.133 billion, a stark contrast to the previous year's profit of $390 million [6]. - The company's various business segments, including skincare and makeup, have experienced revenue declines, with makeup sales down 6% and operating profits in the color cosmetics and fragrance sectors turning negative [6][8]. Group 3: Strategic Shifts and Future Directions - Estée Lauder's new CEO, Stéphane de La Faverie, has initiated a significant transformation strategy called "Beauty Reimagined," focusing on consumer-centric growth and prioritizing investment in high-potential brands [7][10]. - The company is actively evaluating its brand portfolio, with several brands, including Too Faced and Smashbox, potentially on the chopping block due to underperformance [8]. - The strategic shift aims to concentrate resources on luxury and high-growth brands, with over 70% of revenue coming from high-end beauty products like La Mer, while also exploring opportunities in the anti-aging and efficacy-driven segments [10][11].